Optimization of particle size and encapsulation efficiency of vancomycin nanoparticles by response surface methodology

Honary, Soheila; Ebrahimi, Pouneh; Hadianamrei, Roja

doi:10.3109/10837450.2013.846375

Cited by 62 publications

(41 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the findings indicated that if the drug was dissolved in CS solution and TPP was added afterward it had resulted in very low EE (<3%). Honary et al (2014) encapsulated vancomycin in CSNPs and reported 60–69% EE ( Honary et al, 2014 ) while 42–55% after encapsulation of 5-Fluorouracil. The well –characterized CSNPs were further investigated for their antipathogenic and anti-biofilm potential.…”

Section: Discussionmentioning

confidence: 99%

Development of Cefotaxime Impregnated Chitosan as Nano-antibiotics: De Novo Strategy to Combat Biofilm Forming Multi-drug Resistant Pathogens

et al. 2016

View full text Add to dashboard Cite

Frequent incidents of antibiotic-resistant biofilm forming pathogens in community-associated and hospital-acquired infections have become a global concern owing to failure of conventional therapies. Nano-antibiotics (NABs) are de novo tools to overcome the multi-drug resistant mechanisms employed by the superbugs. Inhibition of biofilm formation is one of those strategies to curb multi drug resistance phenomenon. In the current study, the anti-biofilm and antibacterial potential of newly synthesized cefotaxime loaded chitosan based NABs have been investigated. Both bare and cefotaxime loaded NABs were prepared by ionotropic gelation method. They were found carrying positive zeta potential of more than +50 mV, indicating highly stable nano-dispersion. Moreover, microscopic studies revealed their size as less than 100 nm. NABs were tested against clinical isolates of multi drug resistant Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, and methicillin resistant Staphylococcus aureus and wherein they demonstrated broad-spectrum anti-biofilm and anti-pathogenic activity. Thus, in vitro synergistic action of cephalosporin drugs and chitosan polymer at nano-scale in contrast to free antibiotics can be an improved broad-spectrum strategy to thwart resistance mechanisms in both Gram-positive and Gram-negative resistant pathogens.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of Cefotaxime Impregnated Chitosan as Nano-antibiotics: De Novo Strategy to Combat Biofilm Forming Multi-drug Resistant Pathogens

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Statistical optimization techniques are effectively used in diverse fields for various optimization processes, such as metabolite production, metabolite extraction, bacterial cell lysis, etc. [17][18][19] Keeping the potential of statistical optimization techniques in view, researchers have started using various designs of RSM for the formulation optimization of various nanodrug/delivery preparations [20][21][22][23][24][25][26]. However, artificial intelligence (AI)-based optimization techniques alone or in amalgamation with statistical optimization techniques have yet to be used in the formulation optimization of nanodrug preparations.…”

Section: Introductionmentioning

confidence: 99%

Preparation and Evaluation of the ZnO NP–Ampicillin/Sulbactam Nanoantibiotic: Optimization of Formulation Variables Using RSM Coupled GA Method and Antibacterial Activities

et al. 2019

View full text Add to dashboard Cite

Nanoparticles (NPs) possessing antibacterial activity represent an effective way of overcoming bacterial resistance. In the present work, we report a novel formulation of a nanoantibiotic formed using Ampicillin/sulbactam (Ams) and a zinc oxide nanoparticle (ZnO NP). 'ZnO NP-Ams' nanoantibiotic formulation is optimized using response surface methodology coupled genetic algorithm approach. The optimized formulation of nanoantibiotic (ZnO NP: 49.9 µg/mL; Ams: 33.6 µg/mL; incubation time: 27 h) demonstrated 15% enhanced activity compared to the unoptimized formulation against K. pneumoniae. The reactive oxygen species (ROS) generation was directly proportional to the interaction time of nanoantibiotic and K. pneumoniae after the initial lag phase of 18 h as evident from 2s'-7'-Dichlorodihydrofluorescein diacetate assay. A low minimum inhibitory concentration (6.25 µg/mL) of nanoantibiotic formulation reveals that even a low concentration of nanoantibiotic can prove to be effective against K. pneumoniae. The importance of nanoantibiotic formulation is also evident by the fact that the 100 µg/mL of Ams and 25 µg of ZnO NP was required individually to inhibit the growth of K. pneumonia, whereas only 6.25 µg/mL of optimized nanoantibiotic formulation (ZnO NP and Ams in the ratio of 49.9: 33.6 in µg/mL and conjugation time of 27 h) was needed for the same.

show abstract

“…These data were contrary to some studies that indicate a direct relationship between the particle size and EE%; nevertheless, larger nanocarriers exhibit higher EE% . However, others indicated that not only particle size but also some other variables affect EE% . As the relationship between turbidity and lecithin concentration was linear, the trend of the relationship of turbidity and EE% was same as lecithin and EE%.…”

Section: Resultsmentioning

confidence: 99%

A combination therapy of nanoethosomal piroxicam formulation along with iontophoresis as an anti‐inflammatory transdermal delivery system for wound healing

Kazemi

Mombeiny

Tavakol

et al. 2019

International Wound Journal

View full text Add to dashboard Cite

Inflammation accounts as one of the major phases in wound healing, while prolonged and chronic inflammation may lead to adverse pathological conditions. Therefore, transdermal delivery of nonsteroidal anti‐inflammatory (NSAIDs) such as encapsulated piroxicam into a nanocarrier seems to be promising. For the first time, a nanoethosomal piroxicam of <200 nm was prepared and combined with iontophoresis. Results showed that there was a critical point at the concentration of 5 mg lecithin with the smallest particle size. Besides, lecithin concentration had direct and inverse linear relationships with turbidity and pH of nanocarriers, respectively. Moreover, as there was no linear relationship between the lecithin concentration and particle size, the effect of lecithin concentration was dominant on turbidity compared with particle size. It seems that a pH higher than 5.5 disturbed the linear relationship of pH and entrapment efficacy percentage (EE%) while at the pH range of 4 to 5.5, the relationship was linear and EE% gradually decreased with increasing pH. These data showed that an optimised nanocarrier with special physicochemical properties is dominant to the just particle size. Besides, ex vivo permeation studies in rat skin showed that there was no significant difference between the permeation of free drug and ethosomal ones. However, iontophoresis significantly enhanced ethosomal piroxicam permeation compared with the free drug. Overall, these data emphasise the superiority of iontophoresis for the transdermal delivery of nanoethosomal medications while nanoethosomal delivery without iontophoresis did not show significant transdermal potential. To sum up, transdermal nanoethosomal piroxicam along with iontophoresis seems to be promising in wound healing.

show abstract

Optimization of particle size and encapsulation efficiency of vancomycin nanoparticles by response surface methodology

Abstract: The size and EE of vancomycin nanoparticles were optimized by the proposed procedure.

Cited by 62 publications

References 27 publications

Development of Cefotaxime Impregnated Chitosan as Nano-antibiotics: De Novo Strategy to Combat Biofilm Forming Multi-drug Resistant Pathogens

Development of Cefotaxime Impregnated Chitosan as Nano-antibiotics: De Novo Strategy to Combat Biofilm Forming Multi-drug Resistant Pathogens

Preparation and Evaluation of the ZnO NP–Ampicillin/Sulbactam Nanoantibiotic: Optimization of Formulation Variables Using RSM Coupled GA Method and Antibacterial Activities

A combination therapy of nanoethosomal piroxicam formulation along with iontophoresis as an anti‐inflammatory transdermal delivery system for wound healing

Contact Info

Product

Resources

About